Showing results (341-350 of 679) with videos related to

Sort By:
Pageof 68
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2023
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple MyelomaMaría-Victoria Mateos, Ajai Chari, Saad Z Usmani, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 24, 2011
Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignanciesFlorent Malard, Xavier Cahu, Aline Clavert, et al.
Leukemia & Lymphoma|June 30, 2010
Reduced-intensity conditioning allogeneic stem cell transplant for relapsed or transformed aggressive B-cell non-Hodgkin lymphomaAline Clavert, Steven Le Gouill, Eolia Brissot, et al.
European Journal of Haematology|January 11, 2013
Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT)Amandine Le Bourgeois, Elsa Lestang, Thierry Guillaume, et al.
Annals of Hematology|March 16, 2019
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective studySabrina Trudel, Benoît Tessoulin, Maxime Jullien, et al.
Leukemia|May 24, 2020
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysisMeletios A Dimopoulos, Xavier Leleu, Philippe Moreau, et al.
Annals of Hematology|April 29, 2020
Absence of influence of peripheral blood CD34+ and CD3+ graft cell counts on outcomes after reduced-intensity conditioning transplantation using post-transplant cyclophosphamideAlice Garnier, Thierry Guillaume, Pierre Peterlin, et al.
Annals of Hematology|March 16, 2019
Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective studyMaxime Jullien, Sabrina Trudel, Benoit Tessoulin, et al.
Hemasphere|July 3, 2026
Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myelomaBruno Paiva, Irene Manrique, Ethan Thompson, et al.
Blood Cancer Journal|January 11, 2023
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myelomaWee-Joo Chng, Sagar Lonial, Gareth J Morgan, et al.
Pageof 68